Editorials
The Cholesterol Controversy Is Over Why Did It Take so Long? Daniel Steinberg, MD, PhD T he history of medicine is replete with examples of stout resistance to change. The lag time between development of new knowledge and its reduction to practice is directly proportional to that resistance. Sometimes this built-in conservatism of the system is good as, for example, in the case of the resistance to the approval of thalidomide for use in the United States. In other situations, however, conservatism may cost lives by delaying the transfer to practice of interventions that could be life saving. My thesis is that there was such a delay in recognizing the importance of hypercholesterolemia and its management. Why did it take so long for the causative role of hypercholesterolemia in atherosclerosis to become generally accepted by the medical profession? Certainly it was a topic deserving of our closest attention, since for many years close to 50% of the deaths in the United States have been attributable to atherosclerosis and its complications. Yet there continued to be a great deal of resistance well after the causeand-effect relation should have been evident. Even before clinical intervention studies provided the conclusive evidence, the cause-and-effect relation should have been easily read from the wealth of evidence at the biochemical, pathologic, epidemiologic, and clinical levels. But it was not. It is my hope that by examining closely this particular "case history," we can gain insights that will be useful as we go on to try to understand and control other chronic diseases. Chronic diseases are much more difficult to deal with than acute diseases. It is more difficult to establish causal relations unambiguously; it is more time consuming and expensive to prove efficacy of treatment. Perhaps there are some general lessons to be learned from a case history of cholesterol controversy. From it we can perhaps get a better idea ofjust how new ideas are generated and-most important-how those new ideas gain acceptance in the medical marketplace and are eventually reduced to clinical practice.
The Cholesterol Controversy The controversy that swirled around the cholesterol-coronary heart disease problem for so many years has been, to say the least, somewhat heated. Today the controversy is over. Discussion now centers not on whether hypercholesterolemia is a causative factor but rather on how we should best deal with it. In 1984, the National Institutes of Health convened a Consensus Conference on Lowering Blood Cholesterol.' The conference panel, which I was privileged to chair, concluded unanimously that there was a cause-and-effect relation between hypercholesterolemia and coronary heart disease (CHD) risk. The panel issued many recommendations regarding acceptable levels of plasma cholesterol and approaches to dietary and drug treatment. Soon thereafter, there was a similar consensus conference in Europe,2 and many other countries have subsequently followed suit. All participants came to similar conclusions and made similar recommendations. In the United States, the National Cholesterol Education Program, coordinated by the National Heart, Lung, and Blood Institute, is now swinging into full gear to educate practitioners and patients with regard to recognition and management of hypercholesterolemia. 3 The goal is to further reduce CHD morbidity and mortality by controlling hypercholesterolemia. Why has the resolution of the controversy occurred at this particular time? In part, it undoubtedly relates to the recent appearance of new data on the effects of intervention, including among others the results of the Lipid Research Clinics Coronary Primary Prevention Trial,4 the University of Southern California CLAS Study,5 and the Helsinki Heart Study.6 However, the bulk of the evidence supporting the causal role of hypercholesterolemia in atherosclerosis has actually been available to us for a much longer time.
It was more than 75 years ago that experimental atherosclerosis was produced in rabbits by simply feeding them cholesterol.7-8 Furthermore, the fact that patients with familial hypercholesterolemia (extremely high levels of plasma cholesterol) develop extremely premature CHD has been well appreciated for at least 50 years. Yet in 1946, Peters and Van Slyke, in their classic book on clinical chemistry,9 summarized their evaluation as follows: "... . Although there can be no doubt that deposits of lipids, especially cholesterol, are consistent and characteristic features [of atherosclerosis] there is no indication that hypercholesterolemia plays more than a contributory role in their production." As recently as 1957, even the American Heart Association was still not totally persuaded. Their fall newsletter that year carried a front page feature article headlined "Link of Fats to Heart Disease Held Unproved." The first intervention trial results were reported in the late 1950s and early 1960s. It is true that they were small and not terribly well controlled, yet they were positive (reviewed in Leren10). In 1969, Dayton et all' reported the largest dietary intervention study to that time. Again, it was positive, but it reached statistical significance only when several endpoints were pooled. Nevertheless, some were already convinced. The American Heart Association led the way, advocating a general change in the American diet as early as 1961.12 In 1969, in my chairman's address to the AlA Council on Arteriosclerosis, I said, "It is now good medical practice to treat-and I use the word advisedly-people who have definite hyperlipoproteinemia. In short, in 25 years we have come to the point where we are probably preventing a disease that was considered to be an inevitable accompaniment of aging not very long ago." '13 Inquest," and acting as both judge and jury, found the unrepresented defendent guilty, viz: "The time has come to reject advice to substitute polyun-letter to the British Medical Joumal, he concluded that ". . . atheroma . . . is quite unrelated to the cholesterol content of the blood," and took to task the ". . . polyunsaturated fat evangelists .. . " for responding with "offensive innuendoes of malice and commercial influence."'9 The gloves were off! However, at times the two sides were arguing about different questions. Sometimes it was the question of whether hypercholesterolemia was a cause of atherosclerosis; sometimes it was the question of whether a particular change in diet would reduce plasma cholesterol levels and effect a decrease in the incidence of CHD.
Why Did It Take so Long? My purpose, however, is not to review in any detail the specifics of the controversy or the many layers of evidence that finally established the lipid hypothesis. Instead, I hope to identify some of the reasons why it was not accepted at first and why we failed for so long to take action. I suggest that there were at least 10 reasons. Undue Emphasis on the Late, Complex Lesion
The clinical sequelae of atherosclerosis are associated with the fibrous plaque and the complex advanced lesion, not the very early lesions. Understandably, then, most pathologists and investigators tended to focus their attention on these advanced forms of the lesion. It is true that any complete hypothesis will ultimately have to account for all of the components of the lesion, including the extensive cellular proliferation, connective tissue deposition, calcification, and necrosis. However, the complexity of the late lesion is the end result of the interplay of many, many interactions taking place over many, many years. To try to play the film backwards and piece together an explanatory scenario by studying late lesions would seem to be the triumph of hope over reason. Looking at these complex lesions, it is not easy to visualize how they could all be the end result of a modest increase in plasma cholesterol level! Furthermore, it is the space-occupying nature of the lesion that compromises blood flow. So, of course, attention tended to focus on cellular proliferation and connective tissue deposition. For example, the endothelial injury hypothesis as originally put forward by Ross and Glomset, for example, focused on growth factors. 20 Lipid deposition was barely mentioned-it might almost have been an epiphenomenon. It is true that the late lesion includes sizable amounts of lipid, including cholesterol, but in the context of the many other features of the lesion the presence of the lipid does not cry out for a postulate implicating it as fundamentally causative.
In contrast, the relevance of lipids to the fatty streak lesion is readily evident. The fatty streak, however, is a silent, clinically benign lesion. Why study a "lesion" without clinical implications? Once it became evident that the fatty streak was the saturated fats for animal and dairy fats. . "18 In a precursor of many (or perhaps most) of the advanced lesions,21'22 it was easier to become interested in lipoproteins. In fact, we now know that lipoproteins can account for fatty streak formation independent of any loss of endothelial cells and that a high low density lipoprotein (LDL) level may itself be sufficient to lead to a fatty streak. 23 However, the phenomena proposed by Ross and Glomset as consequences of endothelial injury are not unimportant but they may only come into play after the fatty streak has been established. [23] [24] [25] So, the first answer to "Why did it take so long?" is that most pathologists were trying to explain all of the complex features of the advanced lesion and focusing on those aspects of the lesion that appeared most clinically relevant-cellular proliferation and deposition of connective tissue. It was not at all easy for them to see how hypercholesterolemia could possibly be responsible for all of these multiple features. As a result, the cholesterol hypothesis did not win many supporters.
Misguided Search for a Single Cause
A central tenet of clinical medicine is that one should strive to explain the clinical picture, if at all possible, on the basis of a single diagnosis; in the sciences we are taught to seek the single simplest explanation (Occam's Razor). It is not surprising, then, that in approaching atherosclerosis the question was improperly posed. It was asked "Is hypercholesterolemia the cause of atherosclerosis?" instead of "Is hypercholesterolemia a cause of atherosclerosis?" It's the evil Aristotelian excludedmiddle rearing its ugly head once again: "all or none"' and "either/or" rather than ''both'' or even ".all of the above." The "single-causers," finding some patients with normal cholesterol levels but premature CHD, rejected hypercholesterolemia as not relevant in any cases of premature CHD. Today I think we can all agree that atherosclerosis is a disease of multiple causality. In fact, it almost certainly is not even a single disease but more likely a group of different (albeit related) diseases. The same end result-the atheroma-may stem from more than one initiating factor and be reached via different but probably interacting pathways. In some patients, hypercholesterolemia may indeed be the dominant cause; in others, for example, the Japanese with their very high incidence of cerebral atherosclerosis, hypertension may be the dominant cause; in still others, cigarette smoking may be the dominant cause (via mechanisms yet to be elucidated). These risk factors appear to be additive or possibly even synergistic. The Procrustean attempt to make one single pathogenesis fit all just will not wash. There are probably several alternative pathways but (with apologies) all roads lead to atheroma.
Skepticism Regarding the Validity of Animal Models
In 1908, in St. Petersburg, Ignatowski showed that "atherosclerosis" could be produced in rabbits by simply feeding them raw meat or milk and egg yolks.7 His published drawings showed typical fatty streak lesions. Ignatowski believed that the culprit was animal protein. Five years later, another St.
Petersburg physiologist, Anitschkow, showed that it was actually the animal fat that was responsible. 8 Anitschkow even produced experimental atherosclerosis by feeding rabbits pure cholesterol. Now that would seem to be a straightforward and rather persuasive bit of evidence implicating cholesterol! Why was there so little interest and so little followup? Why were these findings, and the subsequent series of studies by Anitschkow in the rabbit, almost dismissed as irrelevant? Several arguments were made.
First, "rabbits are strict vegetarians so feeding them cholesterol-a substance found only in animal products-flies in the face of Nature. The experiment so grossly distorts normal physiology that it cannot have general significance." Of course, some 70 years later, Yoshio Watanabe26 laid this particular objection to rest when he developed his strain of LDL receptor-deficient rabbits. These animals develop atherosclerosis while eating their normal vegetarian chow; their hypercholesterolemia is purely endogenous but they have pervasive atherosclerosis by age 3 months. Moreover, the lesions are almost indistinguishable from those of cholesterol-fed rabbits27 and are really quite similar to human lesions.
Second, "the blood cholesterol levels reached in the cholesterol-fed rabbits are ridiculously high-1,000 mg/dl or more." In retrospect, we would note that those levels are actually not too different from those in patients with homozygous familial hypercholesterolemia. Moreover, later studies in several laboratories showed that you can produce atherosclerosis in rabbits at much lower blood cholesterol levels-as low as 200-300 mg/dl-by just feeding less cholesterol and waiting a little longer. 28 Third, "the appearance of the rabbit lesions is not the same as that of human lesions." This view was based on a comparison with more-advanced human lesions, lesions that develop over decades. The lesions developing in the grossly hyperlipemic, cholesterol-fed rabbit in a matter of months are understandably different, but that does not mean the basis of their formation is different. Considering the enormous differences in vessel size, in the time scale of development, and so on, it is remarkable that the similarities were as great as they were! Later studies showed that given enough time, the predominantly fatty streak lesion of the cholesterolfed rabbit does indeed go on to develop changes that make it more similar to the human lesion. Interestingly, they tend to do that even after the atherogenic diet has been discontinued. 29, 30 Fourth, "the rabbit is unique and the results must not be generalized to other species, let alone to man." It is true that the early attempts to induce atherosclerosis in other laboratory animals were singularly unsuccessful. Dogs and rats, for example, simply did not develop lesions on a cholesterolrich diet. What was overlooked, however, was the fact that neither did these animals show much of a rise in plasma cholesterol level on the cholesterolrich diet! So why should one expect them to get lesions? When Kendall and coworkers31 thyroidectomized dogs (which, we now know, downregulates their LDL receptors) and then fed them the very same diet, their plasma levels of cholesterol did go up and they did develop lesions. During the 1950s and 1960s, it became clear that atherosclerosis can be produced in almost any experimental species if you succeed in raising the cholesterol level sufficiently. In other words, it is not that the so-called resistant species have resistant arteries, it is that their plasma cholesterol levels are less readily raised by dietary manipulation-quite a different thing.
Had the findings of Ignatowski and Anitschkow been less skeptically received, had the similarities to the human disease in its early stages been realized, had the work in other species been more vigorously pursued and analyzed-we might have saved 50 years! Confusion Between Cholesterol in the Diet and Cholesterol in the Blood This point somewhat overlaps the previous one in the sense that the failure to duplicate Anitschkow's results in other species was at first regarded as a fatal blow. It took a long time to clarify the fact that the rabbit model worked so well simply because it was so easy to raise the rabbit's plasma cholesterol level by feeding cholesterol.
A similar confusion has clouded epidemiologic studies over the years. Correlations between dietary cholesterol intake and CHD risk have sometimes been unpersuasive. Within-country studies, including the Framingham study in the United States, have often failed to demonstrate a significant correlation, although correlations are there to be found if looked for carefully. 32 The difficulty in demonstrating a correlation with cholesterol intake is due partly to the fact that the population in Framingham shows a rather narrow spread of cholesterol intakes; in part to the fact that different individuals respond differently to changes in the level of dietary cholesterol intake and in part to the fact that a number of other dietary components in addition to cholesterol influence plasma cholesterol levels. Saturated fat intake is, of course, the most important of these, but dietary fiber intake, dietary protein intake, and many other factors also have their effect. The key point is that the lipid hypothesis relates only collaterally to dietary cholesterol (or to other dietary components); the primary hypothesis is that risk is related to the plasma cholesterol level. Naturally, one might anticipate finding correlations with dietary pattern to the extent that the dietary pattern deter-ure to find a good correlation between dietary composition and risk does not necessarily disprove the underlying hypothesis! Confusion About What Constitutes a "Normal" Plasma Cholesterol Level Traditionally, laboratory values are considered normal if they lie between the 5th and the 95th percentiles of the distribution curve. This is a time-honored criterion that serves well in most instances. However, it simply does not apply when assessing cholesterol levels in the developed countries of the West. In fact, if you go by the dogma for defining "normal," you almost have to reject a priori the notion that hypercholesterolemia is a major cause of coronary atherosclerosis. By definition, only 5% of the population is hypercholesterolemic, yet 50% of the population is dying of CHD! So, the lipid hypothesis makes no sense at all if you accept the 95th percentile definition of normal. Undoubtedly, then, many rejected the lipid hypothesis because so many patients were dying of CHD despite perfectly normal cholesterol levels according to the classic definition of "perfectly normal." Japanese plasma cholesterol levels are notably lower than those in the United States, as is CHD mortality, but both are higher in Japanese who have migrated to Hawaii and even more so in Japanese who have migrated to San Francisco. 33 As the migrants acquire new dietary habits, their mean cholesterol levels go up and so do their death rates from CHD. Clearly, this is not genetic but environmental; probably the major difference is the diet. Even this rather powerful epidemiologic lesson was not fully internalized by our profession at first. Let me offer a parable.
Once upon a time there was a mythical Swiss canton high in the Alps where half the population walked around with huge goiters. A visiting US endocrinologist noted this and pointed out to the Swiss physicians that the average blood levels of thyroid-stimulating hormone (TSH) in this canton were much higher than those in the United States. "But," responded the Swiss doctors, "these levels are normal for our population. You Americans have a very different life-style and possibly a different genetic constitution that probably accounts for the difference. And besides, do not tell us how to practice medicine!' The American gently pointed out that the Swiss who moved out of the canton to New York City showed a sharp drop in their levels of TSH and lost their goiters. "Well," grumbled the Swiss, "So maybe it is not the genes. But anyway, life-style is certainly very different in New York." However, they grudgingly agreed to look into the matter and found that within their population those with the highest TSH levels had the highest probability of developing a goiter! That impressed them. Finally, they ran their TRC-PGPT (Thyroid Research Clinicmines the plasma cholesterol level. However, fail-Primary Goiter Prevention Trial) and found-lo and behold-that iodized salt sharply reduced the risk of goiter. There followed a Swiss National Consensus Conference on Reducing Blood TSH and a National Iodized Salt Education Program, and they all lived happily ever after-or at least without goiters.
Today, of course, we have voluminous data showing the powerful predictive value of plasma cholesterol levels. From the MRFIT study of more than 300,000 men, it is now clear that the risk of CHD is a continuous function of cholesterol levels even within the range we once considered "normal." 34 We know that a great deal may be gained even by what might seem a trivial lowering of cholesterol levels. If risk changes with shifts in cholesterol level, the MRFIT data predict that a relatively modest 17% drop in cholesterol level could lead to a 40% decrease in coronary death rate for men with cholesterol levels initially in the range of 221-244 mg/dl! When we look at the observed decreases in risk associated with decreases in cholesterol levels in intervention studies, we find that the results are consonant with just such a prediction. For example, in the Lipid Research Clinic's Coronary Primary Prevention Trial, the decrease in risk was on average about 19% for a decrease in cholesterol level of about 9%.4 When data for all of the clinical intervention trials are pooled,35 a similar relation unfolds. This is particularly impressive because these studies used very different protocols and means for lowering cholesterol levels. In some, there was only a dietary intervention; in some, drugs were used. Many different drugs were used, including cholestyramine, nicotinic acid, and the fibric acids. These several modalities for lowering cholesterol levels work by different mechanisms; yet the benefit conferred for a given fall in cholesterol level was reasonably constant. This suggests that the plasma cholesterol level itself was the variable that determined risk.
Resistance of the Biomedical Community to the

Need for Synthesizing Data of Several Different
Kinds, Including the Overwhelming Epidemiologic Data, to Conclude That Hypercholesterolemia Is Causative Clinical correlations and formal epidemiologic studies had firmly established hypercholesterolemia as a risk factor for atherosclerosis by the late 1960s. The relation between hypercholesterolemia and CHD was evident in many prevalence studies and then in many prospective studies, including the notable study at Framingham, Massachusetts.36 Now, an epidemiologic correlation by no means establishes a cause-and-effect relation. The ear lobe crease correlates reasonably with CHD risk,37 but no one proposes interventional "lobectomy" to reduce the risk! Epidemiologic correlations can, of course, only suggest the possibility of a cause-and-effect relation. The likelihood that a correlation really indicates a causal relation depends on ancillary considerations. Is the proposed relation reason-able? Are there clearly established hypotheses that would make the causal relation understandable? Is the relation strong and graded? Are there crosscountry studies or, even better, migration studies to support the cause-and-effect relation? Are there intervention studies, even if weak in themselves, that tend to support a causal relation? All of these questions need to be asked before we accept epidemiologic data as a basis for inferring causal relation. In fact, one would generally want to discourage automatic acceptance of epidemiologic correlations as establishing causal relations. However, in the case of the cholesterol controversy, there was considerable ancillary data available that, when considered together with the overwhelming epidemiologic data, should have led to an earlier acceptance of a causal relation.
We already had the clinical observation that genetically determined hypercholesterolemia was associated with premature CHD; we already had the data that lesions were rich in cholesterol and that this cholesterol came from the plasma; we already had the experimental animal models in which atherosclerosis is induced simply by raising cholesterol levels, and so on. Unfortunately, however, too many investigators downgraded the weight of the epidemiologic evidence because they refused to consider it in the proper context.
One last point in this connection. Now that we have the intervention trial data, we see that the decrease in CHD risk induced by a given decrease in plasma cholesterol level is remarkably close to the decrease that would have been predicted from the epidemiologic data.4 That is, lowering a patient's cholesterol level, whether by diet or by drugs or by both, puts the patient into a risk category characteristic of the group who have always had such lower cholesterol levels. Actually the decrease in risk obtained in intervention studies tends to be less than that predicted from the epidemiologic data.
This may be the consequence of the short duration of the intervention trials. Seldom are patients followed for more than 5-7 years, and this may not be long enough to invoke the maximum effect achievable by changing the plasma cholesterol level. Perhaps if the cohorts involved are studied longer, it may turn out that the agreement is even closer. The Weakness of the Early Clinical Prevention Trials When Considered Individually Even though many of the early clinical trials yielded positive results, those results were unconvincing. The numbers were small and the design was in many cases flawed. For example, one of the earliest dietary trials, the Leren Secondary Intervention Trial, achieved a 33% reduction in CHD relapse over 5 years associated with a mean 20% fall in plasma cholesterol level.10 But there were only 206 men in each group, and the result was marginally significant (p=0.011). Another example is the Wadsworth Veterans Administration Primary Pre-vention Study of Dayton et al,11 which was positive but only reached statistical significance by pooling all three endpoints used-new CHD, peripheral vascular disease, and stroke. In retrospect, however, the impact of all the intervention trial data considered together was really very impressive. Richard Peto and coworkers38 compiled the results of all the dietary intervention studies available up to 1981 and analyzed them by a new statistical approach. From the pooled data, it was concluded that there was a statistically highly significant effect of lowering cholesterol levels.
For many people, however, the intervention data were insufficient until the results of the landmark Lipid Research Clinics study were reported in 1984.4 This was a very large, randomized, carefully controlled, double-blind, primary intervention trial. Not only did the trial achieve significance in terms of CHD mortality, as discussed above, but it also provided supportive internal evidence of several kinds. As the investigators reported, the results were concordant both with the results predicted from prospective studies and with the data from other intervention trials, some using drugs and some using diet. Since the completion of the Lipid Research Clinics Study, we have now seen the results of the CLAS Study,5 the Leiden Intervention Study,39 and the Helsinki Heart Trial.6 There is no longer any basis for questioning the causeand-effect relation. The message is that we probably make a mistake in insisting that each intervention study be evaluated on its own. Peto's proposition that we can legitimately pool results of many studies seems now to be further supported by the definitive results reported since that proposal was put forward. It may be important to remember this lesson. As we deal increasingly with chronic diseases, the kinds of problems that attended the CHD intervention trials may be encountered again. To design massive, single trials may become more difficult and forbiddingly expensive. Adopting as a standard operating procedure some pooling techniques, such as that recommended by Peto, may become a necessity.
A Feeling Among Many Practitioners That the Hyperlipidemias Were Too Complex to Deal With and the Treatment Was Difficult and Ineffective
First, we in the metabolic field are guilty of having unnecessarily complicated the picture we presented to the practitioner. We were, understandably, excited about new concepts emerging in a rapidly developing area of research. As a result, we probably overemphasized intriguing but relatively rare abnormalities, leading to complex algorithms that confused rather than clarified. The practitioner got the feeling that before any therapy could be planned he had to go through an intricate process of classification and that put him off. As a result, he was discouraged and often failed even to deal effectively with the garden variety of hypercholesterolemia.
Second, it was commonly believed that diet would reduce cholesterol levels by only a very small percentage and that, therefore, the game was not worth the candle. In retrospect, that was, of course, a misconception. Depending on the starting cholesterol level (and the starting diet), one can expect a drop of 10-20%. Moreover, we now know that such a decrease in cholesterol level can have a very significant impact, reducing CHD risk by as much as 20-40%.
When trying to deal with severe cases of hypercholesterolemia, cases that required drug intervention, the practitioner was faced with a rather short list of available pharmacologic agents. The bile acid-binding resins were the most highly recommended, but too often the patient's reaction was sufficiently negative to discourage the physician from ever prescribing them again! Nicotinic acid was high on the recommended list, but too often the patient complained bitterly about the discomfiting flushing. In some cases, the drug had to be discontinued because of elevated transaminase or decreased glucose tolerance. The last thing the practitioner wants to do is to tell his patient that he has uncovered a problem that requires treatment and then admit that he cannot treat it effectively. Perhaps under those conditions, he will decide to let sleeping dogs lie. Over the years, we have now improved the way we use drug treatment (e.g., combined therapy), and we have seen the advent of new, highly promising agents (e.g., the HMG-CoA reductase inhibitors) that make management easier and more effective.
Preoccupation of the Cardiologists With Elegant New Diagnostic and Interventional Technologies
At about the same time that the cholesterol story was developing and maturing, clinical cardiology was making tremendous advances. The cardiologist was overwhelmed by an almost endless string of new and exciting advances: elegant imaging tools, sophisticated new cardiac care unit maneuvers for salvaging myocardium and for correcting arrhythmias, streptokinase and tissue-type plasminogen activator to dissolve thrombi, coronary bypass surgery, angioplasty, and more. With this veritable technologic overload, it was understandable that the cardiologists were less than receptive to the cholesterol hypothesis and the preventive approaches being recommended. The fact that until recently very few cardiologists did their research on lipoproteins and atherogenesis provided mute testimony to the low standing of the lipid hypothesis. Absence of a Clear, Detailed Hypothesis as to Just How Hypercholesterolemia Gives Rise to the Lesion At the time of Anitschkow's studies, absolutely nothing was known about how lipids were transported in the plasma. Even as recently as 1948, the year the National Heart Institute was established, we knew only that there were two classes of lipoproteins-aand ,B-lipoprotein according to the Cohn fractionation procedure. We knew nothing at all about the apoproteins or their functions. The so-called "clearing factor" had just been identified, but it was not even certain yet that it was an enzyme! Obviously, it was not possible to codify specific hypotheses about cholesterol deposition and the lipoprotein-cell interactions that might lead to lesions until more was known about the cholesterol-carrying lipoprotein system. By the 1970s, we had a much more complete view of the classes of lipoproteins, their origins, interconversions, and metabolic fates, but we still knew relatively little about their metabolism at the cellular level. That kind of knowledge only developed in the late 1970s and during the 1980s, with Michael S. Brown and Joseph L. Goldstein leading the way with their brilliant elucidation of the receptor pathway.40 There then followed a flood of studies capitalizing on the techniques of cell biology to characterize lipoprotein-cell interactions in intimate detail. Only recently, then, has it become possible to spell out some of the important unit processes that might be operative in atherogenesis, piece together explicit hypotheses, and plan how to test their validity in vivo.
So, for many years, even though we might be convinced that hypercholesterolemia was relevant, we had something of a "mechanism gap." As mentioned above, the most widely accepted hypothesis for atherogenesis-the endothelial injury hypothesis-did not assign lipids a central role. 20 In the absence of a plausible mechanism, one is less likely to be persuaded by indirect evidence no matter how definitive. Hypothesis and mechanism are important, not only for the intellectual satisfaction they bring and for their heuristic value but also as a way of winning acceptance for an underlying causeand-effect relation. Today it has become possible to put lipoproteins squarely into the picture. We can now see in principle how lipoproteins can initiate the atherogenic process and play a key role in development of the fatty streak lesion.23 As stressed above, atherosclerosis is a disease of multiple etiology and hyperlipoproteinemia is only one factor. However, the intervention data leave no doubt that it is a quantitatively important factor. By showing how it operates, we may have removed one of the remaining obstacles to the full acceptance of the lipid hypothesis.
Several new findings came together to allow formulation of an explicit theory as to how lipoproteins contribute to atherogenesis.234' One important development was the realization that the fatty streak lesion does not depend on previous loss of endothelial cells from the surface. Previously, it had been supposed that there must be loss of cells to allow platelets to adhere and initiate lesion formation; now we recognize that the fatty streak develops under an intact, unbroken layer of endothelial cells. Another key development was the accumulation of evidence that foam cells are derived predominantly (although not exclusively) from circulating monocytes rather than smooth muscle cells. A third development was the finding by Goldstein et a142 that macrophages express a distinct receptor-the scavenger receptor or acetyl LDL receptor-that is not found on other cell types (except for endothelial cells). It appears that the loading of these macrophages with cholesterol is attributable in large part to uptake of lipoproteins via this acetyl LDL receptor. This receptor does not recognize native LDL and so, rather paradoxically, LDL as it occurs in the plasma would not appear to be a highly atherogenic lipoprotein. Recent studies have shown that there are several ways in which the LDL molecule can be modified such that its uptake by macrophages can be markedly enhanced.4' One such mechanism that is receiving a great deal of attention recently is oxidation of the LDL molecule. Several lines of evidence show that LDL after its entry into the arterial wall may undergo oxidative modification that changes its properties in a number of ways that could contribute to the atherogenic process: it is taken up much more rapidly than is native LDL by the macrophage; it acts as a chemoattractant and can therefore contribute to the recruitment of circulating monocytes from the blood into the artery wall; and it inhibits the motility of the tissue macrophage and may thus prevent its exit from the arterial wall, leading to accumulation of foam cells.41 It is now possible to see how an elevation of plasma LDL concentration in itself could account for the formation of fatty streaks at an accelerated rate. Are these in vitro observations relevant in vivo? Recent studies have shown that prevention of LDL oxidation can indeed slow the progression of experimental atherosclerosis in LDL receptor-deficient rabbits.43,44 Oxidation of LDL also renders it cytotoxic due to the accumulation of oxidized fragments of fatty acids.45 As discussed elsewhere,41 this cytotoxicity may contribute to the transition of the benign fatty streak lesion to the more complicated, clinically significant later lesions of atherosclerosis. It should be mentioned that a number of other modifications of LDL may occur that also enhance its uptake into macrophages in vitro. These changes include aggregation of LDL with itself, formation of immune complexes, and formation of complexes with tissue matrix components. However, the relevance of these modifications in vivo remains to be established.
The central point is that we now have explicit hypotheses as to how lipoproteins can induce and favor the progression of early atherosclerotic lesions. That being the case, it no longer seems quixotic to contend that there is a cause-and-effect relation between hypercholesterolemia and atherosclerosis.
Conclusion
In retrospect, it now seems hard to believe that there was a time when the skeptics far outnumbered the believers in the lipid hypothesis. It seems difficult to believe that people resisted for so long the proposal to transfer to clinical practice what has now become almost an accepted dogma. Such is the history of science and medicine. While the history is still fresh in our minds, it is possibly useful to go back and analyze, as we have tried to do here, why the hypothesis took so long to become accepted. Certainly this analysis is not exhaustive; other factors probably contributed. We have not seen the end of these kinds of perplexing problems even with regard to atherogenesis. As we become more sophisticated in our understanding of the pathogenesis and approach the point where newer modes of intervention can be tested at the clinical level, we shall have to deal again with similar kinds of issues.
What does it take to establish that a proposed intervention is safe and effective and carries a good risk-to-benefit ratio? Some investigators take the position that the only kind of evidence that counts is clinical trial evidence. From one point of view, that position is logical: No matter what one suspects from in vitro studies or animal studies, one cannot know with certainty that the findings will apply to humans. But is it really logical to ignore totally all other kinds of evidence? The data from the early clinical trials of diet and drug treatment of hypercholesterolemia were suggestive but, admittedly, not conclusive. However, those data, considered in the context of the extensive epidemiologic and experimental evidence, strongly suggested that hypercholesterolemia was indeed causative and that intervention would have a beneficial effect. That turned out to be the case. We can anticipate that this kind of issue will recur. While it may seem "antiscientific," it may be not only justifiable but necessary to consider all relevant lines of evidence in reaching a judgment. That judgment will take into account not only the strength of the evidence for a causative relation, but also the kind of intervention, its risks, and its potential benefits. Like most medical decisions, it will have to be made using common sense as well as statistical analyses.
